Shares of PTC Therapeutics surged Monday when the pharmaceutical firm announced it struck a nearly $2 billion license and ...

On Monday, PTC Therapeutics, Inc. (NASDAQ:PTCT) signed an exclusive global license and collaboration agreement with Novartis ...

Swiss drugmaker Novartis will pay up to $2.9 billion for PTC Therapeutics' promising experimental drug for a neurological ...

PTC Therapeutics has signed an up to $2.9 billion licensing deal with Novartis AG for the U.S. company's experimental drug ...

The Swiss pharmaceutical company invests in a PTC Therapeutics program to develop treatment for Huntington’s disease.

PTC Therapeutics surges 21% after entering exclusive global collaboration with Novartis for Huntington's disease program ...

William Blair analyst Sami Corwin has reiterated their bullish stance on PTCT stock, giving a Buy rating on November 27.Don't Miss our Black ...

Wells Fargo keeps an Overweight rating and $68 price target on PTC Therapeutics (PTCT). Investors had been undervaluing the potential value of ...

At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly ...

The potential $2.9 billion deal stands the New Jersey company in good stead after recent disappointing results in its ALS ...

Novartis is paying $1 billion upfront for global rights to PTC Therapeutics’ midphase Huntington's disease program, helping ...

Monday’s agreement comes days after PTC discontinued the development of another asset, utreloxastat, due to disappointing ...